Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)

US10406098B2 · kind B2 · utility

Assignee

• Evonik Röhm GmbH · DE

Inventors

• Norbert Windhab · Hofheim, DE
• Rima Jaber · Frankfurt, DE
• Axel Schroeder · Reinheim, DE
• Kevin Burton · Hoover, US
• Tom Tice · York, US

Key dates

• Filing date: Nov 11, 2016
• Grant date: Sep 10, 2019
• Expiry date: Nov 11, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An injection solution can be used in a pharmaceutical dosage formulation. The injection solution includes an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, where a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.